Steel Dynamics Guides Q1 Profit Well Above Estimates

Steel producer Steel Dynamics Inc. (STLD) on Thursday provided its earnings and adjusted earnings guidance for the first quarter, well above analysts' estimates.

For the first quarter, the company said it expects earnings in a range of $3.47 to $3.51 per share and adjusted earnings in a range of $3.78 to $3.82 per share.

Adjusted earnings exclude the impact from costs associated with the startup of the company's Sinton Texas Flat Roll Steel Mill growth investment of an estimated $78 million, or $0.31 per share.

On average, six analysts polled by Thomson Reuters expect the company to report earnings of $3.11 per share for the quarter. Analysts' estimates typically exclude special items.

The company had reported earnings of $5.71 per share, and adjusted earnings of $6.02 per share in the prior-year quarter.

The company projects first quarter 2023 profitability from its steel operations to be meaningfully stronger than sequential fourth quarter results, based on increased shipments across the platform more than offsetting metal spread compression as average realized selling values associated with lagging indexed-contracts declined in the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT